3 Small Biotech Stocks Insiders Are Buying

I will be sweating out today's Food and Drug Administration (FDA) decision on Zilretta along with most shareholders of Flexion Therapeutics Inc. (FLXN) . Given trial results, insider activity (they were still buying shares in September), analyst views and the price action in the stock, a green light looks like a slam dunk. However, nothing is certain in this high-beta part of the market. I am sure there will bouts of euphoria and downright depression by the day traders on StockTwits throughout the day before the decision is known.

In the meantime, I offer up three other biotech/biopharma stocks that are appearing on my radar. I think they are worth owning at current prices given their attractive risk/reward levels. Insiders also seem to be accumulating stakes in them....362 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.